Immunovant Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-153.2M | $-110.6M | $-126.5M | $-120.6M | $-111.1M | $-109.1M | $-87.2M | $-51.4M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $92.0K | — | — | $107.0K | — | — | $80.0K | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $13.8M | — | — | $18.5M | — | — | $13.5M | — |
| Net Cash from Operating Activities | $-124.4M | $-92.3M | $-102.5M | $-117.4M | $-100.4M | $-88.6M | $-76.2M | $-47.1M |
| Investing Activities | ||||||||
| Capital Expenditures | — | $0 | $0 | $0 | $180.0K | $196.0K | $182.0K | $131.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | — | $0 | — | — | $-182.0K | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $20.1M | — | — | $2.9M | — | — | $686.0K | — |
| Net Change in Cash | $-104.3M | — | — | $-115.1M | — | — | $-75.4M | — |
| Free Cash Flow | — | $-92.3M | $-102.5M | $-117.4M | $-100.6M | $-88.8M | $-76.4M | $-47.2M |